Clinical Trials Directory

Trials / Completed

CompletedNCT00415207

Pharmacogenomics of Paclitaxel in Ovarian Cancer

Pharmacogenomics of Paclitaxel in Ovarian Cancer: Predictors of Toxicity and Response

Status
Completed
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
University of Southern Denmark · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug). Specifically we will study this retrospectively in patients who participated in clinical trials that are now closed. All patients had ovarian cancer and received paclitaxel/carboplatin chemotherapy after primary surgery.

Detailed description

Paclitaxel is an antineoplastic drug used in the treatment of ovarian cancer. The effect and toxicity is unpredictable in the individual patient. Paclitaxel is removed (eliminated) from the organism by oxidation. CYP2C8 is the enzyme mainly responsible. P-glycoprotein (Pgp) is an efflux transport protein natural to the human organism. Pgp is responsible for excretion of drugs via the bile and the kidneys and is thought to play a role in chemotherapy resistance. Paclitaxel is substrate for Pgp. Single nucleotide polymorphisms are possible causes for variation in both CYP2C8 and Pgp expression/function. We will study a possible role of these genetic variations as predictors of paclitaxel toxicity and effect and the possible implications for individual dosing in the future. We will use tissue from patients who participated in one of two clinical trials that are both closed for inclusion. Genotypic data from this tissue will be correlated with toxicity and survival data drawn from a research database. We expect to be able to find \>300 available cases to study.

Conditions

Timeline

Start date
2006-12-01
Primary completion
2008-08-01
Completion
2010-12-01
First posted
2006-12-22
Last updated
2011-08-08

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT00415207. Inclusion in this directory is not an endorsement.